62 results about "Transforming growth factor" patented technology

This invention belongs to the field of nutritional composition technology, specifically disclosing a composition for promoting brain cognitive development, its preparation method, and its application. The composition for promoting brain cognitive development provided by this invention includes transforming growth factor, casein phosphopeptide, immunoglobulin, and sn-2 DHA, and further specifies that the mass ratio of transforming growth factor, casein phosphopeptide, immunoglobulin, and sn-2 DHA is (0.1~1.4) ng:(40000~160000) mg:(20000~60000) mg:(20000~70000) mg. In this invention, the preferred ratio of transforming growth factor, casein phosphopeptide, immunoglobulin, and sn-2 DHA can achieve the effect of promoting brain cognitive development through a multi-dimensional synergistic mechanism.

The invention discloses a serum substitute compatible umbilical cord mesenchymal stem cell culture medium additive composition and application thereof. The serum substitute compatible umbilical cord mesenchymal stem cell culture medium additive composition is prepared from the following components in parts by mass: 15 to 25 parts of platelet-derived growth factor-BB; 15 to 25 parts of basic fibroblast growth factors; 8 to 12 parts of transforming growth factor-beta; and 8-12 parts of recombinant human insulin. The serum substitute compatible umbilical cord mesenchymal stem cell culture medium additive composition and the application thereof disclosed by the invention have the following beneficial effects: (1) the proliferation efficiency is remarkably improved; (2) the cell morphology and dryness can be well maintained; and (3) the compliance and the compatibility are good.

The invention relates to the technical field of biology, in particular to a human CD4 and TGF-beta1 / 2 / 3 combined bispecific antibody which at least comprises a first protein functional area, and the first protein functional area comprises a first antigen binding site targeting CD4; and the second protein functional region comprises a second antigen binding site targeting TGF (Transforming Growth Factor)-beta 1 / 2 / 3. The bispecific antibody disclosed by the invention can be well and specifically combined with CD4 and specifically combined to helper T cells; meanwhile, the bispecific antibody can be combined with TGF beta 1, so that Th1 cell mediated cellular immunity is activated, TGF beta 2 and TGF beta 3 are neutralized, and the bispecific antibody has the effect of preparing the medicine for preventing and treating bacterial infectious diseases.

This invention relates to a skin cell dispersion for autologous treatment of skin wounds. Specifically, this invention provides a skin cell dispersion containing skin cells, epidermal growth factor, and transforming growth factor-β1. The skin cell dispersion of this invention exhibits excellent therapeutic effects on skin wounds.

This invention provides an organ fibrosis-related micropeptide, OFMP, and its applications. This type of micropeptide, OFMP, is a translational product with endogenous biological activity and stable existence, encoded by an open reading frame (ORF) in a long non-coding RNA. It is the first time that the long non-coding RNA encoding the micropeptide has been found to be significantly related to organ fibrosis and can encode the micropeptide. Synthetic peptides prepared based on the aforementioned OFMP micropeptide show significant inhibitory effects on several key indicators of organ fibrosis, including type I collagen α1 chain gene, α-smooth muscle actin, transforming growth factor β1, and connective tissue growth factor. This indicates that the OFMP micropeptide, the nucleotide sequence (ORF) encoding the micropeptide, and the long non-coding RNA sequence containing the nucleotide sequence have important clinical diagnostic and therapeutic value for organ fibrosis.

The invention provides an induced pluripotent stem cell culture medium and a culture method of induced pluripotent stem cells. The induced pluripotent stem cell culture medium comprises a basic culture medium, a composite additive A and a composite additive B, the composite additive A comprises 5-30 [mu] g / mL of recombinant human insulin growth factors, 1-5 ng / mL of recombinant human transforming growth factors, 50-200 ng / mL of recombinant human basic fibroblast growth factors, 7-20 [mu] g / mL of sodium selenite, 0.5-2 mg / mL of albumin, 50-70 [mu] g / mL of ascorbic acid and 5-20 [mu] g / mL of transferrin; the composite additive B is prepared from 50 to 300mg / mL of a Stock B solution, 0.5 to 5 percent (v / v) of a non-essential amino acid solution, 50 to 200ng / mL of DL-piperidinecarboxylic acid, 50 to 200mu g / mL of gamma-aminobutyric acid, 0.1 to 1 percent (v / v) of a lipid concentrated solution, 0.5 to 5 percent (v / v) of an L-alanyl-L-glutamine solution and 0.1 to 0.1 percent of mercaptoethanol. The culture medium for the induced pluripotent stem cells provided by the invention can ensure the self-renewal capability of the iPSCs in a long-term passage process; and the genetic stability of the iPSCs cells is optimized according to the genome integrity and pluripotent state.

The invention discloses a method and a pharmaceutical composition for inhibiting tumor growth by combining an mRNA vaccine and a transforming growth factor-beta (TGF-beta) antibody. The medicine composition comprises an mRNA vaccine for coding a tumor specific antigen and a monoclonal antibody for specifically targeting TGF-beta, and tumor specific immune response induced by the mRNA vaccine is combined with the effect of the TGF-beta antibody for relieving tumor microenvironment immunosuppression, so that the killing ability of a body to tumor cells is remarkably enhanced; the compound provided by the invention can effectively inhibit tumor growth and prolong the lifetime of tumor-bearing individuals, has good safety and tolerance, and provides a new effective strategy for tumor treatment.

A treatment composition for inhibiting systemic sclerosis Vimentin mutant protein activity by using an STAT6 inhibitor, which inhibits the expression of an M2 macrophage and a profibrotic T cell which are immunocytes related to systemic sclerosis, and increases the expression of a Treg, and inhibits the expression of TGF-β, Col1a1, and α-SMA which are fibrosis factors related to systemic sclerosis. The presence of a pSTAT6 expression CD8 T cell in a fibrosis tissue has been identified, and that the expression of a pSTAT6 expression CD8 T positive cell is controlled via injection of the STAT6 inhibitor. In an animal model with increased Vimentin-specific disease symptom activity, the STAT6 inhibitor inhibits antigen-specific tissue fibrosis of systemic sclerosis with activated disease symptoms, and that the STAT6 inhibitor inhibits the expression of IL-17 cytokine expression CD8 positive TRM capable of inducing fibrosis and cell inflammation which are systemic sclerosis diseases.

The invention belongs to the technical field of tissue engineering, and particularly relates to a bio-ink system for osteochondral repair as well as a preparation method and application of the bio-ink system. The system comprises first bio-ink and second bio-ink which are respectively used for simulating cartilage and bone tissue. The first biological ink is prepared from methacrylic acid gelatin, acellular extracellular matrix powder, aldehyde modified natural polysaccharide, a photoinitiator and a transforming growth factor; the second biological ink is prepared from methacrylic acid gelatin, acellular extracellular matrix powder, nano-hydroxyapatite, aldehyde modified natural polysaccharide, a photoinitiator and human bone morphogenetic protein BMP-2. The bio-ink system can guarantee smooth extrusion and interlayer fusion in the printing process; the constructed bionic microenvironment and the affinity effect of the bionic microenvironment on growth factors are suitable for 3D printing construction of the osteochondral integrated bionic scaffold and have good clinical transformation potential.

The invention relates to the field of bone tissue engineering and regenerative medicine, in particular to non-denatured bone protein calcium superfine powder with bone tissue oriented growth and rapid repair effects and a preparation method and application of the non-denatured bone protein calcium superfine powder, and the non-denatured bone protein calcium superfine powder comprises the following components in percentage by weight: 25%-45% of non-denatured type I collagen, 0.005%-0.05% of bone morphogenetic protein-2, 0.001%-0.02% of transforming growth factor-beta1, 0.01%-0.02% of calcium sulfate, 0.01%-0.02% of calcium sulfate, 0.01%-0.02% of calcium The bone tissue repairing agent is prepared from, by weight, 0.001%-0.02% of basic fibroblast growth factors, 20%-40% of ultramicro hydroxyapatite nanoparticles, 5%-15% of chitosan oligosaccharide, 3%-10% of mannitol calcium complex, 2%-8% of sodium hyaluronate, 0.01%-0.1% of vitamin D3, 0.01%-0.1% of vitamin K2, 5%-15% of chondroitin sulfate, 1%-4% of casein phosphopeptides and the balance auxiliary materials, and directional growth and rapid repairing of bone tissue are promoted.

This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, long-term dialysis. For example, prediction of long-term dialysis treatment can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring hyaluronic acid, death receptor 5, and / or transforming growth factor β1 can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury.

This invention proposes a method for preparing dental pulp stem cell exosomes and their applications, belonging to the field of exosome technology. Dental pulp stem cells from exfoliated deciduous teeth are seeded into serum-free α-MEM medium containing microparticles, insulin-like growth factor, transforming growth factor-β1, penicillin, and streptomycin for culture. Exosomes are isolated, dispersed in PBS solution, and incubated with microparticles, propylene glycol, and rhodioloside to obtain highly active dental pulp stem cell exosomes. The surface of these exosomes is then modified with shikonin and interferon to obtain dental pulp stem cell exosomes. The dental pulp stem cell exosomes prepared by this invention exhibit good affinity for titanium implant-mediated osteointegration repair materials, demonstrating good anti-inflammatory, immunomodulatory, osteogenic, and damage-reducing effects. Furthermore, the preparation method is simple, yields high output, and operates under mild conditions, showing broad application prospects.

This invention discloses the use of polylactic acid (PLA) and its copolymers in the preparation of products that promote hair follicle growth and repair, belonging to the field of biomedical technology. Through in vitro and in vivo experiments, this invention demonstrates that PLA can significantly upregulate the expression of lactate dehydrogenase A and transforming growth factor β2 in dermal papilla cells, promoting dermal papilla cell proliferation and hair follicle growth and damage repair. Based on these findings, this invention provides the application of PLA and its copolymers in the preparation of products that promote hair follicle growth and damage repair, offering a safe and effective treatment strategy for hair follicle-related diseases.

The invention belongs to the technical field of biological medicine, and particularly relates to a rheumatism immune disease treatment composition combining traditional Chinese medicine active ingredients and immune regulation and application of the rheumatism immune disease treatment composition, and the rheumatism immune disease treatment composition comprises the following components in parts by weight: 10-50 parts of a traditional Chinese medicine active ingredient compound; 0.01 to 1 part of an immune regulation factor; 50 to 90 parts of pharmaceutic adjuvants; wherein the traditional Chinese medicine active component compound is prepared from the following components: astragaloside, artemisinin, curcumin and triptolide in a weight ratio of (2-5): (1-3): (1-4): (0.5-2); the immunoregulation factor is composed of recombinant human interleukin-10 (rhIL-10), a transforming growth factor-beta1 (TGF-beta1) and a CTLA4-Ig fusion protein according to a weight ratio of (1-3): (0.5-2): (1-4). The active ingredients of the traditional Chinese medicine cover a plurality of links of anti-inflammation, anti-oxidation, immunoregulation and the like, and immunoregulatory factors accurately intervene in immune cell activation and a cell factor network to jointly inhibit abnormal immune response.

The invention provides a dental pulp stem cell exosome as well as a preparation method and application thereof, and belongs to the technical field of exosomes. The method comprises the following steps: inoculating exfoliated deciduous tooth pulp stem cells into a serum-free alpha-MEM culture medium containing microparticles, insulin-like growth factors, transforming growth factor-beta1, penicillin and streptomycin for culturing, separating exosomes, dispersing the exosomes into a PBS solution, adding microparticles, propylene glycol and salidroside for incubation, and separating to obtain the high-activity pulp stem cell exosomes. And performing surface modification on alkannic acid and interferon to prepare the dental pulp stem cell exosome. The dental pulp stem cell exosome prepared by the invention has relatively good affinity to a titanium implant material mediated osseointegration repair material, has relatively good advantages of resisting inflammation, regulating immunity, promoting osteogenesis, reducing injury and the like, is simple in preparation method, relatively high in yield and mild in condition, and has a wide application prospect.

The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-β (TGF-β) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.

The invention discloses a construction method of an in-vitro liver cancer liver invasion and metastasis experimental model, and relates to the technical field of model construction, and the construction method comprises the following steps: culturing liver cancer cells and hepatic stellate cells, carrying out fluorescence labeling, generating a space coordinate set by using the fluorescence labeled liver cancer cells and hepatic stellate cells, and calculating the in-vitro liver cancer liver invasion and metastasis experimental model. The method comprises the following steps of: printing liver cancer cells and hepatic stellate cells according to a space coordinate set to generate a three-dimensional cell-matrix structure, pouring photoresponse hydrogel into the three-dimensional cell-matrix structure, and inducing HOTAIR long non-coding RNA concentration by using a transforming growth factor to obtain the three-dimensional cell-matrix structure integrated with the photoresponse hydrogel. The space coordinate set is generated through the Markov model, accurate simulation of radial distribution of the highly invasive liver cancer cell core area and the hepatic stellate cells is achieved, and an accurate position template is provided for printing of a three-dimensional cell-matrix structure.

5 / 5-5 / 6 bisaryl compounds that inhibit transforming growth factor-β activated kinase (TAK1); compositions comprising the same; and their use for treating cancers and inflammatory diseases.

The invention discloses a preparation method of alpha-ketoisovaleric acid in an anti-hepatic fibrosis drug, and relates to the technical field of hepatic fibrosis treatment drug development, and the preparation method comprises the following steps: mixing alpha-ketoisovaleric acid with pharmaceutic adjuvants to prepare a pharmaceutically acceptable dosage form; the dosage of the alpha-ketoisovaleric acid is determined based on the pharmacological activity of the alpha-ketoisovaleric acid in the concentration range of 50 mu M to 200 mu M, wherein the alpha-ketoisovaleric acid can inhibit hepatic stellate cell activation induced by a transforming growth factor-beta; an endogenous metabolite alpha-ketoisovaleric acid is applied to preparation of an anti-hepatic fibrosis medicine, and based on the pharmacological activity of the alpha-ketoisovaleric acid for specifically inhibiting activation of TGF-beta induced hepatic stellate cells at the concentration of 50-200 mu M, a novel anti-hepatic fibrosis preparation which is high in safety, wide in therapeutic window and free of liver and kidney accumulation risk is developed. The medicine is not only suitable for treating hepatic fibrosis caused by various causes such as non-alcoholic fatty liver disease, viral hepatitis, alcoholic liver disease and drug-induced liver injury, but also meets the requirements of early intervention and severe treatment through reasonable dosage form design and administration route selection.

The invention relates to siRNA of a targeted skin scar promoting gene and application of the siRNA, and belongs to the technical field of biology. The invention provides siRNA (small interfering Ribonucleic Acid) targeting a skin scar promoting gene, and an antisense strand of the siRNA can be specifically combined with the skin scar promoting gene so as to trigger the degradation of the skin scar promoting gene; the skin scar promoting gene is a gene for coding a transforming growth factor 1; a positive-sense strand of the siRNA comprises a nucleic acid molecule with a nucleotide sequence as shown in SEQ ID NO.1, and an antisense strand of the siRNA comprises a nucleic acid molecule with a nucleotide sequence as shown in SEQ ID NO.11. Researches show that the siRNA can target the skin scar promoting gene, is high in interference efficiency, has high inhibitory activity on the skin scar promoting gene, and provides a good theoretical and practical basis for skin scar treatment.

This disclosure belongs to the field of cell culture technology, and specifically relates to a serum-free culture medium for MSCs and its preparation method. The culture medium contains a fixed ratio of basic nutrients and six key regulatory factors, namely transferrin, ascorbic acid, human serum albumin, human fibroblast growth factor rhFGF, platelet-derived growth factor PDGF-BB, and transforming growth factor TGF-β1. By optimizing the combination and concentration of these six key regulatory factors, the proliferation rate and activity of MSCs are significantly improved. It also provides four suitable formulations: high proliferation, high activity, balanced, and economical. The culture effect is stable and reproducible, with high safety and a simple process, making it suitable for laboratory research and large-scale clinical-grade MSC culture.

The invention relates to the technical field of molecular biology and biological medicine, in particular to a siTGF-beta1 / siGAS6 co-delivery system capable of being used for aerosol inhalation synergistic treatment of idiopathic pulmonary fibrosis. Specific siTGF-beta1 is designed aiming at mRNA (messenger ribonucleic acid) of a transforming growth factor TGF-beta1, and the siTGF-beta1, siGAS6 capable of effectively inhibiting GAS6 gene expression and a mannan-polypeptide conjugate carrier are further compounded to form a mannan-polypeptide conjugate co-delivery system of the siTGF-beta1 and the siGAS6, namely a mannan-polypeptide / siTGF-beta1 / siGAS6 co-delivery system. The system can be used for preparing a medicine for treating idiopathic pulmonary fibrosis, especially for preparing a medicine capable of being inhaled by atomization. The idiopathic pulmonary fibrosis can be synergistically treated in an aerosol inhalation mode. According to the technical scheme, lung macrophages can be efficiently targeted, and a synergistic treatment effect is generated to realize efficient treatment on idiopathic pulmonary fibrosis.

The present disclosure provides novel bifunctional antagonist polypeptides containing at least one TNF-α-binding domain and at least one TGF-β-binding domain, which have a high ability to sequester TNF-α and TGF-β in parallel. Pharmaceutical compositions of such bifunctional polypeptide antagonists and their use for treating various complex disease states whose pathogenesis involves activation of both the TNF-α-mediated NF-KB signaling pathway and the TGF-β-mediated Smad2 / 3 signaling pathway are also provided.

This invention relates to a method for evaluating the wound-healing efficacy of mesenchymal stem cell (MSC) populations. Furthermore, this invention relates to a method for selecting MSCs for generating stem cell populations under cGMP conditions, and a method for selecting MSC populations for generating stem cell populations for subsequent drug administration. Additionally, this invention relates to a method for selecting MSC populations for generating a master cell bank, and a method for identifying tissues suitable as starting materials for generating MSC populations for drug use. The method includes measuring the levels of at least two proteins selected from angiopoietin-1 (Ang-1), transforming growth factor-β (TGF-β), vascular endothelial growth factor (VEGF), and hepatocyte growth factor (HGF) secreted by MSCs into the culture medium.

Provided is a computer-implemented method for selecting a subject at risk for developing Crohn's disease, including a trained logistic regression model classifying a subject as at risk for developing Crohn's disease based on blood levels of C-X-C motif chemokine ligand (9), transforming growth factor α, hepatocyte growth factor, C-C motif chemokine ligand (11), matrix metalloproteinase (10), matrix metalloproteinase (1), C-X-C motif chemokine ligand (11), C-C motif chemokine ligand (19), C-C motif chemokine ligand (23), and tumor necrosis factor β.

Provided in the present disclosure are a bifunctional protein which can bind to PD-1 (programmed death receptor-1) and TGF-β (transforming growth factor-β), the medical use of the bifunctional protein, and a preparation method therefor.

This invention provides an antibody combination for detecting transforming growth factor-β1 (TGF-β1), comprising a first antibody and / or a second antibody, each possessing a unique CDR fragment. Specific applications of this antibody combination are also provided. The advantages of this invention are that the antibody combination exhibits strong affinity for TGF-β1 antigen, high detection sensitivity, ease of use, and rapid and stable detection. The concentration of TGF-β1 in normal human serum is 28.4 ± 9.3 pg / ml. Existing conventional low-affinity antibodies are insufficient for effective detection in this situation. However, the high-affinity antibody combination and the TGF-β1 quantitative detection kit containing this antibody combination using a double-antibody sandwich method provided by this invention can effectively achieve the quantitative detection of ultra-low concentrations of TGF-β1. Verification shows that the kit's sensitivity can reach 4.9 pg / mL.

The present invention relates to 5-(4-fluorophenyl)-2,3-dihydro-1H-imidazo[1,2-a]imidazole derivatives of formula (I) as ALK5 inhibitors (transforming growth factor 3 (TGF3) type 1 receptor) for the treatment of fibrosis, such as e.g. pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), hepatic fibrosis, renal fibrosis, ocular fibrosis, cardiac fibrosis, arterial fibrosis and systemic sclerosis. An example with good activity is e.g. example 5: 2-(dimethylamino)-N-(2-fluoro-5-(6-(6-methylpyridin-2-yl)-2,3-dihydro-1H imidazo[1,2-a]imidazol-5-yl)phenyl)acetamide (Formula IA). Pharmacological data is provided: (Table 3)TABLE 3Example NoALK5 pKi2, 9, 10≥9.01, 3, 4, 7, 8, 11, 12, 148.1-8.95, 6, 137.5-8.0

The present invention relates to a fusion protein that specifically binds to the extradomain B of fibronectin (EDB-FN) and transforming growth factor β (TGF-β), and use thereof; and, more specifically, to a fusion protein comprising a polypeptide that specifically binds to EDB-FN and a polypeptide that specifically binds to TGF-β, and use thereof.The fusion protein according to the present invention fixes TGF-β, which plays an important role in antitumor immune responses, to the extracellular matrix, in order to localize the inhibition of TGF-β directly in the tumor microenvironment and ensure a local rather than systemic effect, thus showing an excellent anticancer effect in all carcinomas, including pancreatic cancer, in which the usual TGF-β inhibitors do not act due to the rigidity of the extracellular matrix, so that it can be used effectively for the prevention or treatment of cancer.

The present application relates to a kind of preparation for increasing the excretion capacity of multifunctional stem cell exosome and its application, belong to cell culture technical field.The preparation is composed of culture medium component I and culture medium component II, component I contains transforming growth factor-beta, hepatocyte growth factor etc., for activating stem cell;Component II contains N-acetyl cysteine, vitamin C etc., promote exosome secretion under low oxygen condition.By using two components in a specific order, the exosome secretion amount and biological activity of umbilical cord mesenchymal stem cells can be significantly improved.Compared with the traditional method, the exosome secretion amount treated by the method of the present application is increased by tens of times, and its ability to promote skin fibroblast proliferation and migration is significantly enhanced, so it has important application value in the field of skin repair, tissue regeneration etc..